Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : email@example.com
|Therapy Name||LY3300054 + Necitumumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|LY3300054||Lodapolimab||Immune Checkpoint Inhibitor 94 PD-L1/PD-1 antibody 65||LY3300054 ( Lodapolimab), is a monoclonal antibody against CD274 (PD-L1) that inhibits binding to the PDCD1 (PD1) receptor, potentially resulting in enhanced anti-tumor immune response (PMID: 29712568).|
|Necitumumab||Portrazza||IMC-11F8||EGFR Antibody 30||Portrazza (Necitumumab) is a fully human IgG1 mAb targeting EGFR, leading to the inhibition of downstream targets in the EGFR pathway, and thereby inhibiting cellular proliferation and invasion (PMID: 21154125). Portrazza (necitumumab) is approved for patients with metastatic squamous non-small cell lung cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT02791334||Phase I||LY3300054 + Necitumumab LY3300054 + Ramucirumab LY3300054||A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid Tumors (PACT)||Active, not recruiting|